CATUG and Crystal Bio Establish Strategic Partnership, Launching "CATUG-Crystal" Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services
and CRANBURY, N.J., Feb. 22, 2024 /PRNewswire/ -- CATUG Inc. (CATUG) and Crystal Bio, a member of Crystal Pharmatech, announced today a long-term strategic partnership to provide advanced nucleic acid-based drug analytical services.
- and CRANBURY, N.J., Feb. 22, 2024 /PRNewswire/ -- CATUG Inc. (CATUG) and Crystal Bio, a member of Crystal Pharmatech, announced today a long-term strategic partnership to provide advanced nucleic acid-based drug analytical services.
- CATUG, a distinguished global entity specializing in integrated nucleic acid and drug delivery CRDMO services, is combining capabilities with Crystal Bio, a premier provider of analytical services for biologics in CMC, preclinical development, and clinical stages.
- The two specialized organizations will provide clients with comprehensive nucleic acid services and analytical solutions in the North American market.
- CATUG and Crystal Bio are confident that by combining the local analytical prowess of Crystal Bio with CATUG's proficient expertise in integrated nucleic acids analytical platforms, CATUG-Crystal will deliver best-in-class analytical services and drive advancements in nucleic acid-based drug development to the North American market.